{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:11:09Z","timestamp":1788919869944,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recently, cancer treatment paradigms have shifted dramatically with the advent of immunotherapies, particularly chimeric antigen receptor (CAR) T-cell therapy. Despite it is revolutionary positive outcomes in treating hematologic malignancies, challenges such as severe toxicities, high treatment costs, and limited efficacy in solid tumors persist. This review highlights these limitations and the ongoing need for innovation in CAR T-cell therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main body<\/jats:title>\n                    <jats:p>This manuscript provides a comprehensive review of most current advancements in CAR T-cell therapy, with a focus on targeting its immunotherapeutic principles, modification of T cells for Targeted cancer therapy using T cells, and clinical applications. It explores the key elements of CAR T-cell therapy, containing antigen recognition domain and intracellular signaling domains, which enable T cells to interact with cancer cells and exert cytotoxic effects. The review examines approved therapies, and ongoing clinical trials, Along with obstacles like cytokine release syndrome (CRS), neurotoxicity, along antigen escape mechanisms. Furthermore, innovations in cutting-edge CAR T-cell therapies and personalized treatment approaches are discussed, together with an emphasis on improving safety and efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The manuscript outlines the future outlook on integrating CAR T-cell therapy integrated with other treatments and exploring patient-specific approaches to revolutionize cancer care. This review aims to bridge the existing gaps in research, offering valuable insights for students and researchers in biomedical sciences and oncology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s43046-025-00262-6","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T09:07:13Z","timestamp":1747386433000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["From lab to lifesaver: the rise of CAR T-cell therapy in oncology"],"prefix":"10.1186","volume":"37","author":[{"given":"Shriyash S.","family":"Jangavali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6976-578X","authenticated-orcid":false,"given":"Pallavi B.","family":"Hangargekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balasaheb U.","family":"Gangthade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya A.","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ujwal A.","family":"Havelikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol A.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"issue":"1","key":"262_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej KM, Merhi M, Inchakalody VP, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22(1):1\u201354. https:\/\/doi.org\/10.1186\/s12943-023-01723-z.","journal-title":"Mol Cancer"},{"key":"262_CR2","doi-asserted-by":"publisher","first-page":"91113882","DOI":"10.3389\/fimmu.2023.1113882","volume":"14","author":"A DaeiSorkhabi","year":"2023","unstructured":"DaeiSorkhabi A, Mohamed Khosroshahi L, Sarkesh A, et al. The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies. Front Immunol. 2023;14:91113882. https:\/\/doi.org\/10.3389\/fimmu.2023.1113882.","journal-title":"Front Immunol"},{"key":"262_CR3","doi-asserted-by":"publisher","unstructured":"Abbasi S, Totmaj MA, Abbasi M, Hajazimian S, Goleij P, Behroozi J, Shademan B, Isazadeh A, Baradaran B. Chimeric antigen receptor T (CAR\u2010T) cells: novel cell therapy for hematological malignancies. Cancer med..\u00a012(7), 7844\u20137858. https:\/\/doi.org\/10.1002\/cam4.5551.","DOI":"10.1002\/cam4.5551"},{"issue":"1","key":"262_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-023-01783-1","volume":"22","author":"S Huang","year":"2023","unstructured":"Huang S, Wang X, Wang Y, Wang Y, Fang C, Wang Y, Chen S, Chen R, Lei T, Zhang Y, Xu X. Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies. Mol Cancer. 2023;22(1):1\u201325. https:\/\/doi.org\/10.1186\/s12943-023-01783-1.","journal-title":"Mol Cancer"},{"key":"262_CR5","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20:359\u201371. https:\/\/doi.org\/10.1038\/s41571-023-00754-1.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"262_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-023-01755-5","volume":"22","author":"Z Huang","year":"2023","unstructured":"Huang Z, Chavda VP, Bezbaruah R, Dhamne H, Yang DH, Zhao HB. CAR T-cell therapy for the management of mantle cell lymphoma. Mol Cancer. 2023;22(1):1\u20139. https:\/\/doi.org\/10.1186\/s12943-023-01755-5.","journal-title":"Mol Cancer"},{"key":"262_CR7","doi-asserted-by":"publisher","unstructured":"Chohan KL, Siegler EL, Kenderian SS. CAR-T cell therapy: the efficacy and toxicity balance. current hematologic malignancy reports. 2023;18(2):9\u201318. https:\/\/doi.org\/10.1007\/s11899-023-00687-7.","DOI":"10.1007\/s11899-023-00687-7"},{"key":"262_CR8","doi-asserted-by":"publisher","unstructured":"Kilgour MK, Bastin DJ, Lee SH, Ardolino M, McComb S, Visram A. Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy. Front. Immunol. 2023;.1\u201310. https:\/\/doi.org\/10.3389\/fimmu.2023.1166038.","DOI":"10.3389\/fimmu.2023.1166038"},{"issue":"1","key":"262_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers16010039","volume":"16","author":"A Majumder","year":"2023","unstructured":"Majumder A. Evolving CAR-T-cell therapy for cancer treatment: from scientific discovery to cures. Cancers. 2023;16(1):1\u201328. https:\/\/doi.org\/10.3390\/cancers16010039.","journal-title":"Cancers"},{"issue":"5","key":"262_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers15051414","volume":"15","author":"AS Luksik","year":"2023","unstructured":"Luksik AS, Yazigi E, Shah P, Jackson CM. CAR T cell therapy in glioblastoma: overcoming challenges related to antigen expression. Cancers. 2023;15(5):1\u201318. https:\/\/doi.org\/10.3390\/cancers15051414.","journal-title":"Cancers"},{"issue":"1","key":"262_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-023-00431-0","volume":"12","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Zhou W, Yang J, Yang J, Wang W. Chimeric antigen receptor engineered natural killer cells for cancer therapy. Exp Hematol Oncol. 2023;12(1):1\u201330. https:\/\/doi.org\/10.1186\/s40164-023-00431-0.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"262_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40779-023-00486-4","volume":"10","author":"L Tang","year":"2023","unstructured":"Tang L, Huang ZP, Mei H, Hu Y. Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer. Mil Med Res. 2023;10(1):1\u201333. https:\/\/doi.org\/10.1186\/s40779-023-00486-4.","journal-title":"Mil Med Res"},{"issue":"21","key":"262_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21218000","volume":"21","author":"JY Noh","year":"2020","unstructured":"Noh JY, Seo H, Lee J, Jung H. Immunotherapy in hematologic malignancies: emerging therapies and novel approaches. Int J Mol Sci. 2020;21(21):1\u201323. https:\/\/doi.org\/10.3390\/ijms21218000.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"262_CR14","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","volume":"57","author":"K Wudhikarn","year":"2022","unstructured":"Wudhikarn K, Perales MA. Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy. Bone Marrow Transplant. 2022;57(10):1477\u201388. https:\/\/doi.org\/10.1038\/s41409-022-01756-w.","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"262_CR15","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1080\/14787210.2021.1855143","volume":"19","author":"O Bupha-Intr","year":"2021","unstructured":"Bupha-Intr O, Haeusler G, Chee L, Thursky K, Slavin M, Teh B. CAR-T cell therapy and infection: a review. Expert Rev Anti Infect Ther. 2021;19(6):749\u201358. https:\/\/doi.org\/10.1080\/14787210.2021.1855143.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"262_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ebiom.2022.103941","volume":"77","author":"D Gumber","year":"2022","unstructured":"Gumber D, Wang LD. Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion. EBioMedicine. 2022;77:1\u201312. https:\/\/doi.org\/10.1016\/j.ebiom.2022.103941.","journal-title":"EBioMedicine"},{"key":"262_CR17","doi-asserted-by":"publisher","unstructured":"Zhang X, Zhang H, Lan H, Wu J, Xiao Y. CAR-T cell therapy in multiple myeloma: current limitations and potential strategies. Front. Immunol. 2023:1\u201313. https:\/\/doi.org\/10.3389\/fimmu.2023.1101495","DOI":"10.3389\/fimmu.2023.1101495"},{"issue":"Suppl 1","key":"262_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/hon.2591","volume":"37","author":"D Sermer","year":"2019","unstructured":"Sermer D, Brentjens R. CAR T-cell therapy: full speed ahead. Hematol Oncol. 2019;37(Suppl 1):95\u2013100. https:\/\/doi.org\/10.1002\/hon.2591.","journal-title":"Hematol Oncol"},{"issue":"1","key":"262_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-022-01559-z","volume":"21","author":"A Dimitri","year":"2022","unstructured":"Dimitri A, Herbst F, Fraietta JA. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Mol Can. 2022;21(1):1\u201313. https:\/\/doi.org\/10.1186\/s12943-022-01559-z.","journal-title":"Mol Can"},{"issue":"1","key":"262_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.36401\/JIPO-22-7","volume":"6","author":"SA Srour","year":"2023","unstructured":"Srour SA, Akin S. Chimeric antigen receptor T-cell therapy for solid tumors: the past and the future. J Immunother Precis Oncol. 2023;6(1):19\u201330. https:\/\/doi.org\/10.36401\/JIPO-22-7.","journal-title":"J Immunother Precis Oncol"},{"issue":"1186383","key":"262_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2023.1186383","volume":"14","author":"W Li","year":"2023","unstructured":"Li W, Pan X, Chen L, Cui H, Mo S, Pan Y, Shen Y, Shi M, Wu J, Luo F, Liu J. Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy. Front Immunol. 2023;14(1186383):1\u201316. https:\/\/doi.org\/10.3389\/fimmu.2023.1186383.","journal-title":"Front Immunol"},{"key":"262_CR22","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1182\/bloodadvances.2022009462","volume":"7","author":"O Pasvolsky","year":"2023","unstructured":"Pasvolsky O, Kebriaei P, Shah BD, Jabbour E, Jain N. Chimeric antigen receptor T therapy for adult B-cell acute lymphoblastic leukemia: state-of the-(C) ART and the road ahead. Blood Adv. 2023;7:3350\u201360. https:\/\/doi.org\/10.1182\/bloodadvances.2022009462.","journal-title":"Blood Adv"},{"issue":"1","key":"262_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers16010046","volume":"16","author":"C Benevolo Savelli","year":"2023","unstructured":"Benevolo Savelli C, Clerico M, Botto B, Secreto C, Cavallo F, Dellacasa C, Busca A, Bruno B, Freilone R, Cerrano M, Novo M. Chimeric antigen receptor-T cell therapy for lymphoma: new settings and future directions. Cancers. 2023;16(1):1\u201323. https:\/\/doi.org\/10.3390\/cancers16010046.","journal-title":"Cancers"},{"issue":"11","key":"262_CR24","doi-asserted-by":"publisher","first-page":"e21776","DOI":"10.1111\/bjh.17544","volume":"9","author":"C Wang","year":"2023","unstructured":"Wang C, Wang J, Che S, Zhao H. CAR-T cell therapy for hematological malignancies: History, status and promise. Heliyon. 2023;9(11):e21776. https:\/\/doi.org\/10.1111\/bjh.17544.","journal-title":"Heliyon"},{"key":"262_CR25","doi-asserted-by":"publisher","first-page":"1188049","DOI":"10.3389\/fimmu.2023.1188049","volume":"14","author":"A Mitra","year":"2023","unstructured":"Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B. From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol. 2023;14:1188049.","journal-title":"Front Immunol"},{"key":"262_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fimmu.2023.1188049","volume":"15","author":"A Mitra","year":"2023","unstructured":"Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B. From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol. 2023;15:14. https:\/\/doi.org\/10.3389\/fimmu.2023.1188049.","journal-title":"Front Immunol"},{"issue":"4","key":"262_CR27","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.apsb.2018.03.001","volume":"8","author":"Z Zhao","year":"2018","unstructured":"Zhao Z, Chen Y, Francisco NM, Zhang Y, Wu M. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharm Sin B. 2018;8(4):539\u201351. https:\/\/doi.org\/10.1016\/j.apsb.2018.03.001.","journal-title":"Acta Pharm Sin B"},{"key":"262_CR28","doi-asserted-by":"publisher","unstructured":"Huang J, Huang X, Huang J. CAR-T cell therapy for hematological malignancies: limitations and optimization strategies. Front. Immunol. 2022:1\u201320. https:\/\/doi.org\/10.3389\/fimmu.2022.1019115.","DOI":"10.3389\/fimmu.2022.1019115"},{"issue":"8","key":"262_CR29","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.3324\/haematol.2022.282316","volume":"108","author":"W Sun","year":"2023","unstructured":"Sun W, Liang AB, Huang H, Huang XJ. Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience. Haematologica. 2023;108(8):2011\u201328. https:\/\/doi.org\/10.3324\/haematol.2022.282316.","journal-title":"Haematologica"},{"issue":"3","key":"262_CR30","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s13770-022-00515-8","volume":"20","author":"S Shin","year":"2023","unstructured":"Shin S, Lee P, Han J, et al. Nanoparticle-based chimeric antigen receptor therapy for cancer immunotherapy. Tissue Eng Regen Med. 2023;20(3):371\u201387. https:\/\/doi.org\/10.1007\/s13770-022-00515-8.","journal-title":"Tissue Eng Regen Med"},{"issue":"19","key":"262_CR31","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1097\/CM9.0000000000002549","volume":"136","author":"Z Yang","year":"2023","unstructured":"Yang Z, Wang Y. Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies. Chin Med J (Engl). 2023;136(19):2285\u201396. https:\/\/doi.org\/10.1097\/CM9.0000000000002549.","journal-title":"Chin Med J (Engl)"},{"issue":"4","key":"262_CR32","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","volume":"29","author":"J Mahdi","year":"2023","unstructured":"Mahdi J, Dietrich J, Straathof K, et al. Tumor inflammation-associated neurotoxicity. Nat Med. 2023;29(4):803\u201310. https:\/\/doi.org\/10.1038\/s41591-023-02276-w.","journal-title":"Nat Med"},{"issue":"38","key":"262_CR33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41375-023-02065-x","volume":"2023","author":"C Li","year":"2024","unstructured":"Li C, Xu J, Luo W, Liao D, Xie W, Wei Q, et al. Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma. Leukemia. 2024;2023(38):149\u201359. https:\/\/doi.org\/10.1038\/s41375-023-02065-x.","journal-title":"Leukemia"},{"issue":"13","key":"262_CR34","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ, et al. GPRC5D-targeted CAR T cells for myeloma. N Engl J Med. 2022;387(13):1196\u2013206. https:\/\/doi.org\/10.1056\/NEJMoa2209900.","journal-title":"N Engl J Med"},{"issue":"1","key":"262_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-023-01894-9","volume":"22","author":"F Ramezani","year":"2023","unstructured":"Ramezani F, Panahi Meymandi AR, Akbari B, et al. Outsmarting trogocytosis to boost CAR NK\/T cell therapy. Mol Can. 2023;22(1):1\u201314. https:\/\/doi.org\/10.1186\/s12943-023-01894-9.","journal-title":"Mol Can"},{"key":"262_CR36","doi-asserted-by":"publisher","unstructured":"CorradoBenevolo Savelli, Clerico M, Botto B, Secreto C, Cavallo F, Chiara Dellacasa, et al. Chimeric antigen receptor-T cell therapy for lymphoma: new settings and future directions. Cancers. 2023;16(1):46\u20136.https:\/\/doi.org\/10.3390\/cancers16010046","DOI":"10.3390\/cancers16010046"},{"key":"262_CR37","doi-asserted-by":"publisher","unstructured":"Amor\u00f3s-P\u00e9rez B, Rivas-Pardo B, G\u00f3mez del Moral M, Subiza JL, Mart\u00ednez-Naves E. State of the art in CAR-T cell therapy for solid tumors: is there a sweeter future? Cells. 2024 ;13(9):725. https:\/\/doi.org\/10.3390\/cells13090725","DOI":"10.3390\/cells13090725"},{"issue":"7","key":"262_CR38","doi-asserted-by":"publisher","first-page":"6300","DOI":"10.3390\/ijms24076300","volume":"24","author":"RC De Marco","year":"2023","unstructured":"De Marco RC, Monzo HJ, Ojala PM. CAR T cell therapy: a versatile living drug. Int J Mol Sci. 2023;24(7):6300. https:\/\/doi.org\/10.3390\/ijms24076300.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"262_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):1\u201311. https:\/\/doi.org\/10.1038\/s41408-021-00459-7.","journal-title":"Blood Cancer J"},{"issue":"4","key":"262_CR40","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","volume":"25","author":"N Frey","year":"2019","unstructured":"Frey N, Porter D. Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant. 2019;25(4):e123\u20137. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.756.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"19","key":"262_CR41","doi-asserted-by":"publisher","first-page":"6124","DOI":"10.3390\/jcm12196124","volume":"12","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Qin D, Shou AC, Liu Y, Wang Y, Zhou L. Exploring CAR-T cell therapy side effects: mechanisms and management strategies. J Clin Med. 2023;12(19):6124. https:\/\/doi.org\/10.3390\/jcm12196124.","journal-title":"J Clin Med"},{"issue":"3","key":"262_CR42","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3322\/caac.21771","volume":"73","author":"RH Parikh","year":"2023","unstructured":"Parikh RH, Lonial S. Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice. CA Cancer J Clin. 2023;73(3):275\u201385. https:\/\/doi.org\/10.3322\/caac.21771.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"262_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2023.2275457","volume":"19","author":"DT Peters","year":"2023","unstructured":"Peters DT, Savoldo B, Grover NS. Building safety into CAR-T therapy. Hum VaccinImmunother. 2023;19(3):1\u20138. https:\/\/doi.org\/10.1080\/21645515.2023.2275457.","journal-title":"Hum VaccinImmunother"},{"issue":"1","key":"262_CR44","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/imr.12772","volume":"290","author":"SS Chandran","year":"2019","unstructured":"Chandran SS, Klebanoff CA. T cell receptor-based cancer immunotherapy: emerging efficacy and pathways of resistance. Immunol Rev. 2019;290(1):127\u201347. https:\/\/doi.org\/10.1111\/imr.12772.","journal-title":"Immunol Rev"},{"issue":"5","key":"262_CR45","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/bjh.17544","volume":"195","author":"K Sanber","year":"2021","unstructured":"Sanber K, Savani B, Jain T. Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells. Br J Haematol. 2021;195(5):660\u20138. https:\/\/doi.org\/10.1111\/bjh.17544.","journal-title":"Br J Haematol"},{"key":"262_CR46","doi-asserted-by":"publisher","unstructured":"Savoldo B, Grover N, Dotti G. CAR T cells for hematological malignancies. The Journal of Clinical Investigation. 2024 Jan 16;134(2). https:\/\/doi.org\/10.1172\/JCI177160","DOI":"10.1172\/JCI177160"},{"key":"262_CR47","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1146\/annurev-med-051914-021702","volume":"67","author":"CA Ramos","year":"2016","unstructured":"Ramos CA, Heslop HE, Brenner MK. CAR-T Cell Therapy for Lymphoma. Annu Rev Med. 2016;67:165\u201383. https:\/\/doi.org\/10.1146\/annurev-med-051914-021702.","journal-title":"Annu Rev Med"},{"issue":"1","key":"262_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells13010101","volume":"13","author":"A Czaplicka","year":"2024","unstructured":"Czaplicka A, Lachota M, P\u0105czek L, Zago\u017cd\u017con R, Kaleta B. Chimeric antigen receptor T cell therapy for pancreatic cancer: a review of current evidence. Cells. 2024;13(1):1\u201316. https:\/\/doi.org\/10.3390\/cells13010101.","journal-title":"Cells"},{"issue":"7","key":"262_CR49","doi-asserted-by":"publisher","first-page":"7844","DOI":"10.1002\/cam4.5551","volume":"12","author":"S Abbasi","year":"2023","unstructured":"Abbasi S, Totmaj MA, Abbasi M, et al. Chimeric antigen receptor T (CAR-T) cells: novel cell therapy for hematological malignancies. Cancer med. 2023;12(7):7844\u201358. https:\/\/doi.org\/10.1002\/cam4.5551.","journal-title":"Cancer med"},{"issue":"1","key":"262_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biomedicines9010059","volume":"9","author":"E Zmievskaya","year":"2021","unstructured":"Zmievskaya E, Valiullina A, Ganeeva I, Petukhov A, Rizvanov A, Bulatov E. Application of CAR-T cell therapy beyond oncology: autoimmune diseases and viral infections. Biomedicines. 2021;9(1):1\u201313. https:\/\/doi.org\/10.3390\/biomedicines9010059.","journal-title":"Biomedicines"},{"issue":"2","key":"262_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/HS9.0000000000000188","volume":"3","author":"S Charrot","year":"2019","unstructured":"Charrot S, Hallam S. CAR-T Cells: future perspectives. Hemasphere. 2019;3(2):1\u201318. https:\/\/doi.org\/10.1097\/HS9.0000000000000188.","journal-title":"Hemasphere"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00262-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-025-00262-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00262-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T09:07:17Z","timestamp":1747386437000},"score":1,"resource":{"primary":{"URL":"https:\/\/jenci.springeropen.com\/articles\/10.1186\/s43046-025-00262-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["262"],"URL":"https:\/\/doi.org\/10.1186\/s43046-025-00262-6","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"28 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}